Metsera, Inc. (MTSR) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है New York City, NY, United States. वर्तमान CEO हैं Christopher Whitten Bernard.
MTSR के पास है IPO तिथि 2025-01-31, 93 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $7.43B.
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral hormone analog peptides designed to treat obesity, overweight, and related metabolic disorders. The company's pipeline includes MET-097i and MET-233i for obesity and overweight management, as well as MET-002, MET-224o, MET-067i, and MET-034i for treating conditions including diabetes and obesity. Founded in 2022 and based in New York, Metsera is advancing nutrient-stimulated therapeutic candidates toward clinical development.
